133 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
CRSP CRISPR Therapeutics AG $50.31 $2.39B N/A
Article Searches
SGMO, CRSP, EPZM and HEAR among notable after hour movers https://seekingalpha.com/news/3471589-sgmo-crsp-epzm-hear-among-notable-hour-movers?source=feed_news_all Jun 14, 2019 - Top Gainers: HCHC+3.3%. EPZM +2.1%. ACA +2.1%. FVRR +1.9%. HEAR +1.6%.Top Losers: CRSP -2.9%. NEW -2.7. SGMO -2.1%. EROS -1.8%. NNBR -1.2%.
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash http://www.zacks.com/stock/news/428419/biotech-stock-roundup-celgene-submits-ms-drug-to-fda-insy-cbay-crash?cid=CS-ZC-FT-428419 Jun 12, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Is the Newest Gene Editing Stock a Buy? https://www.fool.com/investing/2019/06/11/is-the-newest-gene-editing-stock-a-buy.aspx?source=iedfolrf0000001 Jun 11, 2019 - Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.
Here's Why Crispr Therapeutics Rose as Much as 18.7% Today https://www.fool.com/investing/2019/06/07/heres-why-crispr-therapeutics-rose-as-much-as-187.aspx?source=iedfolrf0000001 Jun 07, 2019 - The richest gene-editing company just got a whole lot richer.
DOCU, BYND, CRSP and GES among notable after hour movers https://seekingalpha.com/news/3469716-docu-bynd-crsp-ges-among-notable-hour-movers?source=feed_news_all Jun 06, 2019 - Top Gainers: ZUMZ +17.3%. BYND +14.3%. ZM +10%. CRSP +8.5%. ELGX +4%.Top Losers: DOCU -20.5%. DOMO -18.1%. OLLI -3.1%. GES -1.8%.
Here's Why CRISPR Gene Editing Stocks Lost as Much as 17% in May https://www.fool.com/investing/2019/06/04/heres-why-crispr-gene-editing-stocks-lost-as-much.aspx?source=iedfolrf0000001 Jun 04, 2019 - First-quarter earnings results from three gene-editing companies gave Wall Street analysts pause.
Vertex Selects Triple Combo Regimen for Regulatory Submission http://www.zacks.com/stock/news/422781/vertex-selects-triple-combo-regimen-for-regulatory-submission?cid=CS-ZC-FT-422781 May 31, 2019 - Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.
CRISPR Therapeutics (CRSP) Presents At Annual Meeting of the American Society of Gene and Cell Therapy - Slideshow https://seekingalpha.com/article/4259008-crispr-therapeutics-crsp-presents-annual-meeting-american-society-gene-cell-therapy-slideshow?source=feed_sector_healthcare May 02, 2019 - The following slide deck was published by CRISPR Therapeutics AG in conjunction with this event.
What's in Store for Vertex (VRTX) This Earnings Season? http://www.zacks.com/stock/news/398972/whats-in-store-for-vertex-vrtx-this-earnings-season?cid=CS-ZC-FT-398972 Apr 24, 2019 - On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
Top Gene-Sequencing Stocks for 2019 https://www.fool.com/investing/2019/04/19/top-gene-sequencing-stocks-for-2019.aspx?source=iedfolrf0000001 Apr 19, 2019 - These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Pages: 123456...14

Page 1>